NO20052959L

Iontophoretic delivery of rotigotine for the treatment of parkinson's disease

Abstract

Using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol / l, where the composition has a pH of 4-6.5 in a lontophoretic device for treating Parkinson's disease, it was possible to achieve a rotigotine flux. over the human stratum corneum which was higher than that previously obtained with conventional passive diffusion systems.

Term

No projected expiry on record.

  1. Priority
  2. Filed and published
  3. Today

1 claim: 1 independent, 0 dependent

  1. 1
    Sammendrag Summary Using a composition comprising rotigotine and at least one chloride salt at a concentration of 1-140 mmol / l, where the composition has a pH of 4-6.5 in an iontophoretic device for treating Parkinson's disease, it was possible to achieve a rotigotine flux. over the human stratum corneum that was higher than that previously achieved with conventional passive diffusion systems. Ved å benytte en sammensetning som omfatter rotigotin og minst ett kloridsalt i en konsentrasjon på 1-140 mmol/1, hvor sammensetningen har en pH på 4-6,5 i en iontoforetisk anordning for behandling av Parkinsons sykdom var det mulig å oppnå en rotigotinfluks over det humane stratum comeum som var høyere enn den som tidligere ble oppnådd med konvensjonelle passive diffusjonssystemer.